Neos Therapeutics, Inc. (NEOS)
Stock Price:
$0.573 USD
-0.001 (-0.23%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $0.570 -0.003 (-0.52%) Nov 27, 4:34 PM
Key Info
| Market Cap |
28.51M |
| Revenue (ttm) |
56.99M |
| Net Income (ttm) |
-21.86M |
| Shares Out |
49.76M |
| EPS (ttm) |
-0.44 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$0.573 |
| Previous Close |
$0.574 |
| Change ($) |
-0.001 |
| Change (%) |
-0.23% |
| Day's Open |
0.560 |
| Day's Range |
0.560 - 0.606 |
| Day's Volume |
522,823 |
| 52-Week Range |
0.450 - 1.980 |
More Stats
| Market Cap |
28.51M |
| Enterprise Value |
59.71M |
| Earnings Date (est) |
Mar 18, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
49.76M |
| Float |
48.43M |
| EPS (basic) |
-0.44 |
| EPS (diluted) |
-0.44 |
| FCF / Share |
-0.14 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.13M |
| Short Ratio |
1.30 |
| Short % of Float |
4.40% |
| Beta |
1.73 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
0.50 |
| PB Ratio |
n/a |
| Revenue |
56.99M |
| Operating Income |
-13.39M |
| Net Income |
-21.86M |
| Free Cash Flow |
-6.99M |
| Net Cash |
-31.20M |
| Net Cash / Share |
-0.63 |
| Gross Margin |
69.35% |
| Operating Margin |
-23.50% |
| Profit Margin |
-38.40% |
| FCF Margin |
-12.26% |
| ROA |
-10.71% |
| ROE |
n/a |
| ROIC |
-45.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (4)
| Buy |
3 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$5.50*
(859.86% upside)
Low
1.00
Current: $0.573
High
10.00
Target: 5.50
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 64.65 | 49.99 | 27.13 | 10.03 | 3.79 | 0.76 | 1.04 |
| Revenue Growth | 29.33% | 84.24% | 170.43% | 164.58% | 400.26% | -27.39% | - |
| Gross Profit | 39.53 | 23.06 | 13.10 | -1.70 | -2.14 | -2.63 | -1.49 |
| Operating Income | -10.42 | -43.50 | -56.54 | -75.82 | -26.58 | -18.47 | -17.09 |
| Net Income | -16.90 | -51.68 | -65.77 | -82.75 | -30.78 | -20.85 | -15.63 |
| Shares Outstanding | 49.72 | 32.29 | 24.75 | 16.05 | 7.58 | 0.88 | 0.79 |
| Earnings Per Share | -0.34 | -1.60 | -2.66 | -5.16 | -4.38 | -27.56 | -28.45 |
| Operating Cash Flow | -10.78 | -41.44 | -53.26 | -70.65 | -25.87 | -17.39 | -14.96 |
| Capital Expenditures | -1.09 | -1.36 | -2.50 | -3.55 | -1.02 | -0.34 | -2.02 |
| Free Cash Flow | -11.87 | -42.80 | -55.76 | -74.20 | -26.89 | -17.73 | -16.97 |
| Cash & Equivalents | 24.89 | 46.48 | 50.42 | 39.78 | 90.76 | 16.34 | - |
| Total Debt | 48.87 | 51.77 | 59.83 | 63.52 | 34.24 | 24.77 | - |
| Net Cash / Debt | -23.98 | -5.30 | -9.42 | -23.74 | 56.52 | -8.43 | - |
| Assets | 90.87 | 111 | 104 | 80.14 | 123 | 45.23 | - |
| Liabilities | 97.00 | 104 | 95.16 | 81.69 | 44.14 | 124 | - |
| Book Value | -6.13 | 7.85 | 8.95 | -1.55 | 78.37 | -78.78 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Neos Therapeutics, Inc. |
| Country |
United States |
| Employees |
213 |
| CEO |
Gerald W. McLaughlin |
Stock Information
| Ticker Symbol |
NEOS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: NEOS |
| IPO Date |
July 23, 2015 |
Description
Neos Therapeutics, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.